{
    "clinical_study": {
        "@rank": "26912", 
        "acronym": "SAFE 21", 
        "arm_group": [
            {
                "arm_group_label": "Non Invasive Prenatal Testing", 
                "arm_group_type": "Experimental", 
                "description": "Blood sample"
            }, 
            {
                "arm_group_label": "Invasive Prenatal Testing", 
                "arm_group_type": "Active Comparator", 
                "description": "CVS or amniocentesis"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized controlled trial in women at risk following combined prenatal screening\n      for Down Syndrome. Women will be asked about their preferences between NIPT and routine\n      prenatal diagnosis based on a dedicated questionnaire. Women will then be randomized between\n      NIPT and standard invasive prenatal diagnosis."
        }, 
        "brief_title": "Non Invasive Prenatal Testing of Down Syndrome", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Down Syndrome", 
        "condition_browse": {
            "mesh_term": "Down Syndrome"
        }, 
        "detailed_description": {
            "textblock": "This is a randomized controlled trial in women at risk following combined prenatal screening\n      for Down Syndrome. Women will be asked about their preferences between NIPT and routine\n      prenatal diagnosis based on a dedicated questionnaire. Women will then be randomized between\n      NIPT and standard invasive prenatal diagnosis.\n\n      The general objectives are :\n\n        -  Promote the rapid and large implementation of Non Invasive Prenatal Testing (NIPT) for\n           Down syndrome.\n\n        -  Improve the management of women at risk after combined first trimester screening and\n           reduce the number of invasive procedures and induced miscarriages .\n\n        -  Evaluate NIPT medically (in reducing the rate of invasive sampling and related\n           complications, diagnostic performance and feasibility and acceptability in routine\n           practice) and based on cost-analysis in comparison with standard invasive prenatal\n           diagnosis currently proposed .\n\n        -  Clarify the conditions of implementation and dissemination of NIPT in the overall\n           organization of prenatal screening for trisomy 21 (and provide data to later adjust or\n           not the combination of tests and thresholds).\n\n      Promote the organization as networks of professionals involved in prenatal screening for\n      trisomy 21 in order to allow the emergence of a national system of collection of outcomes to\n      improve the quality of practices\n\n      The main judgement criteria are:\n\n        -  Main:\n\n           - Percentage of fetal loss in each group\n\n        -  Secondary:\n\n             -  Percentage of invasive tests in each group (amniocentesis or chorionic villus\n                sampling )\n\n             -  Diagnostic performance of NIPT , in particular false positive and negative\n\n             -  Percentage of results within 3 weeks and average time interval for results of NIPT\n\n             -  Percentage of inconclusive results of DPANI\n\n             -  Percentage of other anomalies discovered at invasive sampling\n\n             -  Percentage of invasive samples taken despite normal NIPT (either because of later\n                ultrasound anomaly or for maternal reinsurance)\n\n             -  Association between maternal characteristics ( weight, height, parity , previous\n                history , serum markers ... ) and the results of NIPT\n\n             -  Cost analysis of NIPT in routine clinical practice\n\n      The study will include 2450 high risk women in order to be powered enough to detect a 1%\n      reduction of miscarriages in the group undergoing NIPT instead of routine invasive prenatal\n      diagnosis."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  pregnant women over 18\n\n          -  at risk for Down syndrome> 1/250 based on combined screening using ultrasound\n             together with maternal serum markers and prior to fetal karyotyping\n\n          -  singleton pregnancy\n\n          -  pregnancy between 11SA et 18SA\n\n          -  willing a  fetal karyotype\n\n        Exclusion Criteria:\n\n          -  risk for Down syndrome< 1/250 or >1/5\n\n          -  NT> 3 mm, PAPP-A or beta HCG <0.3 MoM or >5 MoM\n\n          -  multiple pregnancy , vanishing twin\n\n          -  morphological abnormalities at US\n\n          -  Kown chromosomal anomaly in parents\n\n          -  Patients not willing a fetal karyotype"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "2450", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02127515", 
            "org_study_id": "P130601", 
            "secondary_id": "2013-A00998-37"
        }, 
        "intervention": [
            {
                "arm_group_label": "Non Invasive Prenatal Testing", 
                "intervention_name": "Non Invasive Prenatal Testing", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Invasive Prenatal Testing", 
                "intervention_name": "Invasive Prenatal Testing", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Down, trisomy 21", 
            "NIPT", 
            "Amniocentesis", 
            "miscarriage", 
            "invasive", 
            "prenatal", 
            "screening."
        ], 
        "lastchanged_date": "May 7, 2014", 
        "location": {
            "contact": {
                "email": "laurence.bussieres@nck.aphp.fr", 
                "last_name": "Laurence Bussi\u00e8res, PhD", 
                "phone": "1 44 49 43 26", 
                "phone_ext": "+33"
            }, 
            "contact_backup": {
                "email": "laurence.lecomte@nck.aphp.fr", 
                "last_name": "Laurence Lecomte, PhD", 
                "phone": "1 71 19 64 94", 
                "phone_ext": "+33"
            }, 
            "facility": {
                "address": {
                    "city": "Paris", 
                    "country": "France", 
                    "zip": "75015"
                }, 
                "name": "H\u00f4pital Necker- Enfants Malades"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Non Invasive Prenatal Testing of Down Syndrome From Maternal Blood Sample", 
        "overall_contact": {
            "email": "laurence.bussieres@nck.aphp.fr", 
            "last_name": "laurence Bussieres, PhD", 
            "phone": "6 17 35 65 83", 
            "phone_ext": "+33"
        }, 
        "overall_contact_backup": {
            "email": "laurence.lecomte@nck.aphp.fr", 
            "last_name": "laurence lecomte", 
            "phone": "1 71 19 64 94", 
            "phone_ext": "+33"
        }, 
        "overall_official": [
            {
                "affiliation": "AP-HP", 
                "last_name": "Laurent J Salomon, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "AP-HP", 
                "last_name": "Michel VEKEMANS, MD, PhD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number or miscarriages", 
            "safety_issue": "Yes", 
            "time_frame": "at birth"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02127515"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number or invasive tests", 
                "safety_issue": "Yes", 
                "time_frame": "at birth"
            }, 
            {
                "measure": "false positive and negative rates of NIPT", 
                "safety_issue": "Yes", 
                "time_frame": "At birth"
            }, 
            {
                "measure": "Dedicated questionnaire for patients", 
                "safety_issue": "No", 
                "time_frame": "day 5"
            }, 
            {
                "description": "measure in euros", 
                "measure": "Cost of invasive tests and NIPT in euros", 
                "safety_issue": "No", 
                "time_frame": "at birth"
            }
        ], 
        "source": "Assistance Publique - H\u00f4pitaux de Paris", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Assistance Publique - H\u00f4pitaux de Paris", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}